Dupont Capital Management Corp acquired a new position in Albany Molecular Research, Inc. (NASDAQ:AMRI) during the second quarter, according to its most recent filing with the SEC. The fund acquired 98,208 shares of the biotechnology company’s stock, valued at approximately $2,131,000. Dupont Capital Management Corp owned approximately 0.24% of Albany Molecular Research at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in AMRI. Royce & Associates LP increased its stake in Albany Molecular Research by 17.6% in the first quarter. Royce & Associates LP now owns 1,518,276 shares of the biotechnology company’s stock worth $21,301,000 after buying an additional 227,365 shares in the last quarter. Vanguard Group Inc. increased its stake in Albany Molecular Research by 6.4% in the first quarter. Vanguard Group Inc. now owns 1,320,055 shares of the biotechnology company’s stock worth $18,521,000 after buying an additional 79,155 shares in the last quarter. Chicago Capital Management LLC bought a new stake in Albany Molecular Research during the second quarter worth approximately $21,417,000. Walthausen & Co. LLC increased its stake in Albany Molecular Research by 16.0% in the first quarter. Walthausen & Co. LLC now owns 831,285 shares of the biotechnology company’s stock worth $11,663,000 after buying an additional 114,430 shares in the last quarter. Finally, AMI Asset Management Corp increased its stake in Albany Molecular Research by 4.3% in the second quarter. AMI Asset Management Corp now owns 735,876 shares of the biotechnology company’s stock worth $15,969,000 after buying an additional 30,383 shares in the last quarter. 66.51% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) opened at 21.73 on Friday. Albany Molecular Research, Inc. has a 12-month low of $13.01 and a 12-month high of $22.17. The stock’s market cap is $905.40 million. The company’s 50-day moving average is $21.71 and its 200-day moving average is $18.21.
TRADEMARK VIOLATION WARNING: “Dupont Capital Management Corp Invests $2.13 Million in Albany Molecular Research, Inc. (AMRI)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://stocknewstimes.com/2017/08/19/dupont-capital-management-corp-invests-2-13-million-in-albany-molecular-research-inc-amri.html.
AMRI has been the topic of a number of research analyst reports. First Analysis downgraded shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a report on Monday, June 12th. William Blair reissued an “outperform” rating on shares of Albany Molecular Research in a report on Tuesday, May 23rd. BidaskClub raised shares of Albany Molecular Research from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Morgan Stanley downgraded shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective on the stock. in a report on Thursday, May 11th. They noted that the move was a valuation call. Finally, J P Morgan Chase & Co downgraded shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a report on Thursday, June 8th. Five analysts have rated the stock with a hold rating, Albany Molecular Research presently has a consensus rating of “Hold” and an average target price of $18.00.
Albany Molecular Research Company Profile
Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.
Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research, Inc. (NASDAQ:AMRI).
Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
